CAMBRIDGE, Mass. March 10, 2021 – Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that the Company’s management team will participate in the Oppenheimer 31st Annual...
– Dr. White joins Apnimed as Distinguished Scientist and Chair of the company’s Scientific Advisory Board – – Additionally, Luigi Taranto Montemurro, M.D., promoted to Chief Scientific Officer – CAMBRIDGE, Mass. March 04, 2021 – Apnimed, a clinical-stage company...
– Data from this study anticipated in first half of 2021 – – AD109 is a disease-modifying therapeutic for the treatment of Obstructive Sleep Apnea – –1-month open label extension study to be conducted following double-blind placebo-controlled study to demonstrate...
